![Teva's generic of Concerta® Extended-Release Tablets [CII]: Methylphenidate Hydrochloride Extended-Release Tablets, USP CII Teva's generic of Concerta® Extended-Release Tablets [CII]: Methylphenidate Hydrochloride Extended-Release Tablets, USP CII](https://www.tevagenerics.com/globalassets/products/image//M-N/Meth0727.png)
Teva's generic of Concerta® Extended-Release Tablets [CII]: Methylphenidate Hydrochloride Extended-Release Tablets, USP CII
![Teva Canada Announces the Launch of <C>ACT Methylphenidate ER® Tablets, a Generic Version of <C>Concerta® for the Treatment of ADHD Teva Canada Announces the Launch of <C>ACT Methylphenidate ER® Tablets, a Generic Version of <C>Concerta® for the Treatment of ADHD](https://mma.prnewswire.com/media/657121/Teva_Canada_Limited_Teva_Canada_Announces_the_Launch_of__ACT_M.jpg?w=500)
Teva Canada Announces the Launch of <C>ACT Methylphenidate ER® Tablets, a Generic Version of <C>Concerta® for the Treatment of ADHD
![Teva's generic of Concerta® Extended-Release Tablets [CII]: Methylphenidate Hydrochloride Extended-Release Tablets, USP CII Teva's generic of Concerta® Extended-Release Tablets [CII]: Methylphenidate Hydrochloride Extended-Release Tablets, USP CII](https://www.tevagenerics.com/globalassets/products/image//M-N/Meth0725.png)
Teva's generic of Concerta® Extended-Release Tablets [CII]: Methylphenidate Hydrochloride Extended-Release Tablets, USP CII
![Differences in the In Vitro and In Vivo Pharmacokinetic Profiles of Once-Daily Modified-Release Methylphenidate Formulations in Canada: Examination of Current Bioequivalence Criteria - ScienceDirect Differences in the In Vitro and In Vivo Pharmacokinetic Profiles of Once-Daily Modified-Release Methylphenidate Formulations in Canada: Examination of Current Bioequivalence Criteria - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0149291812000896-gr2.jpg)
Differences in the In Vitro and In Vivo Pharmacokinetic Profiles of Once-Daily Modified-Release Methylphenidate Formulations in Canada: Examination of Current Bioequivalence Criteria - ScienceDirect
![Differences in Adverse Event Reporting Rates of Therapeutic Failure Between Two Once-daily Extended-release Methylphenidate Medications in Canada: Analysis of Spontaneous Adverse Event Reporting Databases - Clinical Therapeutics Differences in Adverse Event Reporting Rates of Therapeutic Failure Between Two Once-daily Extended-release Methylphenidate Medications in Canada: Analysis of Spontaneous Adverse Event Reporting Databases - Clinical Therapeutics](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/a54cba3c-6801-4c70-87bf-4597ffc38fb5/gr1_lrg.jpg)